The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials

@article{Czernichow2011TheEO,
  title={The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials},
  author={S{\'e}bastien Czernichow and Alberto Zanchetti and Fiona M Turnbull and Federica Barzi and Toshiaru Ninomiya and Andr{\'e} Pascal Kengne and Hiddo J. Lambers Heerspink and Vlado Perkovic and Rachel R. Huxley and Hisatomi Arima and Anushka Patel and John Chalmers and Mark Woodward and Stephen MacMahon and Bruce Neal},
  journal={Journal of Hypertension},
  year={2011},
  volume={29},
  pages={4–16}
}
Background The benefits of reducing blood pressure are well established, but there remains uncertainty about whether the magnitude of the effect varies with the initial blood pressure level. The objective was to compare the risk reductions achieved by different blood pressure-lowering regimens among individuals with different baseline blood pressures. Methods Thirty-two randomized controlled trials were included and seven comparisons between different types of treatments were made. For each… 

Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels – overview and meta-analyses of randomized trials

TLDR
Meta-analyses favor BP-lowering treatment even in grade 1 hypertension at low-to-moderate risk, and lowering SBP/DBP to less than 140/90 mmHg appears safe, but only adds further reduction in stroke.

Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs – Overview and meta-analyses

TLDR
BP lowering by all classes of antihypertensive drugs is accompanied by significant reductions of stroke and major cardiovascular events, which supports the concept that reduction of these events is because of BP lowering per se rather than specific drug properties.

Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials

TLDR
Individuals with very high cardiovascular risk due to symptomatic cardiovascular disease should consider BP-lowering treatment even when their BP is in the high-normal and normal range, according to a meta-analyzing of randomized controlled trials.

Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials

TLDR
It is suggested that BP-lowering pharmacotherapy is effective in lowering BP, up to 4 years on average, in people with different characteristics, and Appropriate treatment strategies are needed to sustain substantive long-term BP reductions.

Effect of antihypertensive drug treatment on long-term blood pressure reduction: An individual patient-level data meta-analysis of 352,744 Participants from 51 large-scale randomised clinical trials

TLDR
Pharmacological agents were effective in lowering long-term BP among individuals with a wide range of characteristics, but the net between-group reductions were modest, which is partly attributable to the intended trial goals.

EFFECTS OF BLOOD PRESSURE LOWERING DRUGS IN HEART FAILURE

TLDR
Treatment with drugs with blood pressure ‐ lowering properties resulted in a small but significant decrease in systolic blood pressure in patients with heart failure with no evidence that the efficacy and safety of those drugs varied according to baseline blood pressure.

Effects of blood pressure-lowering drugs in heart failure: a systematic review and meta-analysis of randomized controlled trials.

TLDR
Treatment with drugs with BP-lowering properties resulted in a small but significant decrease in SBP in patients with heart failure with no evidence that the efficacy and safety of those drugs varied according to baseline BP.

The Blood Pressure Lowering Treatment Trialists’ Collaboration: methodological clarifications of recent reports

TLDR
The power of pooled analyses of the Blood Pressure Lowering Treatment Trialists’ Collaboration dataset in filling long-standing gaps in knowledge is demonstrated, and some misconceptions regarding the methods underpinning the recent reports are clarified.

Cumulative in-trial and post-trial effects of blood pressure and lipid lowering: systematic review and meta-analysis

TLDR
Benefits of BPL and lipid lowering on all-cause and cardiovascular mortality were persistent, but attenuated, after discontinuation of randomized treatment, indicating the importance of continuing therapy.
...

References

SHOWING 1-10 OF 40 REFERENCES

Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.

TLDR
These overviews showed that the short- to-medium-term effects on major cardiovascular events of the BP-lowering regimens studied were broadly comparable for patients with and without diabetes.

Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials

TLDR
Reduction of blood pressure produces benefits in younger and older adults, with no strong evidence that protection against major vascular events afforded by different drug classes varies substantially with age.

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

TLDR
All the classes of blood pressure lowering drugs have a similar effect in reducing CHD events and stroke for a given reduction in blood pressure, indicating that the benefit is explained by blood pressure reduction itself.

Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials.

TLDR
All of the blood pressure-lowering regimens studied here provided broadly similar protection against major cardiovascular events in men and women, suggesting differences in cardiovascular risks between sexes are unlikely to reflect differences in response to blood pressure -lowering treatments.

Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?

TLDR
In high-risk patients there is a ‘ceiling effect’ for treatment benefits, and delaying therapeutic correction of cardiovascular risk factors until a high level of risk is achieved blunts the full benefits of interventions.

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study

TLDR
In high-risk patients, the benefits from SBP lowering below 130 mmHg are driven mostly by a reduction of stroke; myocardial infarction is unaffected and cardiovascular mortality is unchanged or increased.

Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack

TLDR
This blood-pressure-lowering regimen reduced the risk of stroke among both hypertensive and non-hypertensive individuals with a history of stroke or transient ischaemic attack, irrespective of their blood pressure.